# Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape

Source: https://onco.cc/key-papers/paper-upadhaya-nat-rev-drug-discov/  
OnCo record `paper-upadhaya-nat-rev-drug-discov` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Paper cited by two bottleneck pages and eleven idea pages, indexed on Europe PMC as PubMed record 35145263 and published in Nature Reviews Drug Discovery; the citing pages link this DOI, which is how the record was matched.

## Summary

Europe PMC indexes no abstract for this record; the title is the only text available.

Indexed on Europe PMC as PubMed record 35145263 (DOI 10.1038/d41573-022-00030-4). Matched by DOI alone: two bottleneck pages and eleven idea pages cite this DOI among their external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Nature Reviews Drug Discovery
- Year: 2022
- DOI: 10.1038/d41573-022-00030-4
- Authors: Upadhaya S, Neftelinov ST, Hodge J, et al.
- What it means: Two bottleneck pages and eleven idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Caveats: Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.

## Sources

- Nat Rev Drug Discov 2022: https://doi.org/10.1038/d41573-022-00030-4
- PubMed: https://pubmed.ncbi.nlm.nih.gov/35145263/
- Europe PMC: https://europepmc.org/article/MED/35145263

## Connected records

- bottlenecks: [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Too many combinations to test](https://onco.cc/bottlenecks/b-combination-space/)
- ideas: [A repurposing label pathway with short exclusivity that non-profits can hold](https://onco.cc/ideas/idea-fund-repurposing-indication-exclusivity/), [An abbreviated approval path for follow-on antibodies within a validated class](https://onco.cc/ideas/idea-fund-abbreviated-pathway-me-too-biologics/), [Extra exclusivity for sponsors who run treatment-duration and de-escalation trials](https://onco.cc/ideas/idea-fund-duration-trial-exclusivity/), [Government reinsurance for phase 2 failures of first-in-class cancer drugs](https://onco.cc/ideas/idea-fund-phase-two-failure-reinsurance/), [Hospital-based CAR-T manufacturing at cost through a public network](https://onco.cc/ideas/idea-fund-public-car-t-manufacturing/), [Milestone prizes for first-in-class mechanisms reaching human proof of concept](https://onco.cc/ideas/idea-fund-first-in-class-prize/), [Outcome-based annuity payments for potentially curative one-time therapies](https://onco.cc/ideas/idea-fund-pay-for-cure-annuities/), [Patent term extension scaled to proven survival gain](https://onco.cc/ideas/idea-fund-value-based-patent-extension/), [Require head-to-head trials against the best in class for later entrants](https://onco.cc/ideas/idea-fund-head-to-head-mandate/), [Shorter exclusivity for later-in-class drugs without added benefit](https://onco.cc/ideas/idea-fund-benefit-indexed-exclusivity/), [Social impact bonds for cancer prevention, repaid from avoided treatment costs](https://onco.cc/ideas/idea-fund-social-impact-bonds-prevention/)
- journals: [Nature Reviews Drug Discovery](https://onco.cc/journals/nature-reviews-drug-discovery/)

---
JSON: https://onco.cc/api/v1/entities/paper-upadhaya-nat-rev-drug-discov.json